General Notices

• The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Regional Workshop on Sexual and Gender Minority (SGM)-Related Health Research
  (NOT-OD-20-074)
  Office of the Director, NIH
  

• Request for Information (RFI) on Implementation of the Updated AVMA Guidelines for the Euthanasia of Animals: 2020 Edition
  (NOT-OD-20-069)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice to update NIH HIV/AIDS Research Priorities and Guidelines in NOT-AR-20-005, "Notice of Special Interest: Promoting research opportunities on HIV/AIDS in NIAMS."
  (NOT-AR-21-005)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of NIDDK Withdrawal from Participation in PA-19-116 "Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)"
  (NOT-DK-20-013)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to the Application Due Date for PAR-20-105 titled "Laboratory Flexible Funding Model (LFFM) (U19) Clinical Trials Not Allowed"
  (NOT-FD-20-009)
  Food and Drug Administration
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)
  (NOT-OD-20-076)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN)
  (NOT-CA-20-014)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Going Global: Using Gene Network Analyses to Understand the Etiology of SUD
  (NOT-DA-20-020)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Administrative Supplements for Research on Womens Health in the IDeA States
  (NOT-GM-20-017)
  National Institute of General Medical Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Institute of Nursing Research
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for the NNLM Web Services Office, Training Office, and the Evaluation Office to Support NNLM All of Us Activities.
  (NOT-LM-20-007)
  National Library of Medicine
  

Funding Opportunities

• Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
  (PAR-20-116)
  National Cancer Institute
  Application Receipt Date(s): May 21, 2020; November 19, 2020; May 20, 2021; November 18, 2021
  
  

• Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)
  (PAR-20-117)
  National Institute of General Medical Sciences
  Application Receipt Date(s): October 2, 2020; October 4, 2021; October 3, 2022
  
  

• National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)
  (PAR-20-118)
  National Institute of Mental Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): July 27, 2020; November 25, 2020; March 25, 2021; July 26, 2021; November 26, 2021; March 25, 2022
  
  

• National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U19 Clinical Trial Optional)
  (PAR-20-119)
  National Institute of Mental Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): July 27, 2020; November 25, 2020; March 25, 2021; July 26, 2021; November 26, 2021; March 25, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Alzheimers Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)
  (RFA-AG-21-006)
  National Institute on Aging
  Application Receipt Date(s): July 1, 2020
  
  

• National Longitudinal Study of Adolescent to Adult Health (Add Health) Wave 6 (U01 Clinical Trial Not Allowed)
  (RFA-AG-21-008)
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Application Receipt Date(s): May 18, 2020. No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional)
  (RFA-AG-21-016)
  National Institute on Aging
  Application Receipt Date(s): July 23, 2020. No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Partnerships for the Development of Universal Influenza Vaccines (R21/R33 Clinical Trial Not Allowed)
  (RFA-AI-20-003)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 2, 2020
  
  

• Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional)
  (RFA-AI-20-008)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 23, 2020 All applications s are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed)
  (RFA-AI-20-009)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 29, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
  (RFA-AI-20-019)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 15, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21/R33 Clinical Trial Not Allowed)
  (RFA-DA-21-004)
  National Institute on Drug Abuse
  Application Receipt Date(s): July 20, 2020
  
  

• Contraceptive Development Research Centers (CDRC) Program (P50 Clinical Trial Optional)
  (RFA-HD-21-011)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): January 6, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Limited Competition: Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-MD-20-007)
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): ?May 5, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)
  (RFA-MH-20-128)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): September 3, 2020 and September 2, 2021 No late applications will be accepted for this Funding Opportunity Announcement.